Advice
Following a 2nd resubmission.
Pemetrexed (Alimta®) is accepted for restricted use within NHS Scotland for monotherapy for the second-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) other than predominantly squamous cell histology. It is restricted to use in patients with good performance status who would otherwise be eligible for treatment with docetaxel.
In a retrospective unplanned sub-group analysis of a study comparing pemetrexed with another agent used in the second line treatment of NSCLC, treatment with pemetrexed resulted in an additional median survival of 1.3 months in patients with a non-squamous histology.
Download detailed advice95KB (PDF)
Medicine details
- Medicine name:
- pemetrexed (Alimta)
- SMC ID:
- 342/07
- Indication:
- monotherapy for second line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology
- Pharmaceutical company
- Eli Lilly and Company Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Resubmission
- Status
- Restricted
- Date advice published
- 08 September 2008